Clinical Trial

GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a single-arm, open-label and early exploratory clinical study, with the purpose to study the safety, tolerability and initial clinical efficacy of GC012F Injection in the treatment of refractory GMG and to evaluate the PK, PD characteristics and immunogenicity in subjects with refractory GMG infused with GC012F Injection.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-30.
Status change: Not Yet Recruiting → Recruiting 2025-09-05
Trial Details
NCT Number NCT07058298
Lead Sponsor Daishi Tian
Collaborators: Gracell Biotechnologies (Shanghai) Co., Ltd.
Conditions Generalized Myasthenia Gravis (gMG)
Enrollment 6 participants
Start Date 2025-07-15
Primary Completion 2027-02-13 (estimated)
Study Completion 2027-09-10 (estimated)
Updated on ClinicalTrials.gov 2025-09-08